Treatment with paclitaxel plus carboplatin, alone or with irradiation, of advanced or recurrent endometrial carcinoma

Gynecologic Oncology

Volumn 104, Issue 1, 2007, Pages 32-35

  Arimoto, Takahide ^a   Nakagawa, Shunsuke ^a   Yasugi, Toshiharu ^a   Yoshikawa, Hiroyuki ^b   Kawana, Kei ^a   Yano, Tetsu ^a   Taketani, Yuji ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Carboplatin; Endometrial cancer; Paclitaxel

Indexed keywords

CARBOPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; RANITIDINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANAPHYLAXIS; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; DYSPNEA; ENDOMETRIUM CARCINOMA; FATIGUE; FEMALE; HEMATOLOGIC DISEASE; HUMAN; HYPERSENSITIVITY; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RADIATION DOSE; RECURRENT CANCER; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; COMBINED MODALITY THERAPY; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL;

EID: 33846022391     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.07.038     Document Type: Article

References (18)

1. Rose P.G. Endometrial carcinoma. N. Engl. J. Med. 335 (1996) 640-649
2. Thigpen J.T., Brady M.F., Homesley H.D., Malfetano J., DuBeshter B., Burger R.A., et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J. Clin. Oncol. 22 (2004) 3902-3908
3. Thigpen J.T., Blessing J.A., and Homesley H. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 33 (1989) 68-70
4. Long H.J., Pfeifle D.M., and Wieand H.S. Phase II evaluation of carboplatin in advanced endometrial carcinoma. J. Natl. Cancer Inst. 80 (1988) 276-278
5. Burke T.W., Munkarah A., Kavanagh J.J., Morris M., Levenback C., Tornos C., et al. Treatment of advanced or recurrent endometrial carcinoma with single-agent carboplatin. Gynecol. Oncol. 51 (1993) 397-400
6. Ball H.G., Blessing J., Lentz S., and Mutch D.C. A phase II trial of Taxol in advanced and recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol. Oncol. 62 (1996) 278-281
7. Price F.V., Edwards R.P., Kelley J.L., Kunschner A.J., and Hart L.A. A trial of outpatient paclitaxel and carboplatin for advanced, recurrent, and histologic high-risk endometrial carcinoma: preliminary report. Semin. Oncol. 24 (1997) S15-78-S15-82
8. Hoskins P.J., Swenerton K.D., Pike J.A., Wong F., Lim P., Acquino-Parsons C., et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J. Clin. Oncol. 19 (2001) 4048-4053
9. Nakamura T., Onishi Y., Yamamoto F., Kouno S., Maeda Y., and Hatae M. Evaluation of paclitaxel and carboplatin in patients with endometrial cancer. Jpn. J. Cancer Chemother. 27 (2000) 257-262
10. Akram T., Maseelall P., and Fanning J. Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer. Am. J. Obstet. Gynecol. 192 (2005) 1365-1367
11. Michener C.M., Peterson G., Kulp B., Webster K.D., and Markman M. Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma. J. Cancer Res. Clin. Oncol. 131 (2005) 581-584
12. Onda T., Yoshikawa H., Mizutani K., Mishima M., Yokota H., Nagano H., et al. Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy. Br. J. Cancer 75 (1997) 1836-1841
13. Fleming T.R. One-sample multiple testing procedure for Phase II clinical trials. Biometrics 38 (1982) 143-151
14. Kaplan E., and Meier F. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 58 (1958) 457-481
15. Markman M., Kennedy A., Webster K., Kulp B., Peterson G., and Belinson J. Persistent chemosensitivity to platinum and/or paclitaxel in metastatic endometrial cancer. Gynecol. Oncol. 73 (1999) 422-423
16. Lincoln S., Blessing J.A., Lee R.B., and Rocereto T.F. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 88 (2003) 277-281
17. Sendo T., Sakai N., Itoh Y., Ikesue H., Kobayashi H., Hirakawa T., et al. Incidence and risk factors for paclitaxel hypersensitivity during ovarian cancer chemotherapy. Cancer Chemother. Pharmacol. 56 (2005) 91-96
18. Yahata H., Saito M., Sendo T., Itoh Y., Uchida M., Hirakawa T., et al. Prophylactic effect of pemirolast, an antiallergic agent, against hypersensitivity reactions to paclitaxel in patients with ovarian cancer. Int. J. Cancer 118 (2006) 2636-2638